- Home
- HBB vs PRLD Comparison
HBB vs PRLD Comparison
Compare HBB & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HBB | PRLD |
|---|---|---|
| Founded | 1904 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 236.4M | 207.5M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HBB | PRLD |
|---|---|---|
| Price | $17.99 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.67 |
| AVG Volume (30 Days) | 22.6K | ★ 290.5K |
| Earning Date | 04-29-2026 | 03-10-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | N/A | ★ 23.21 |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $606,852,000.00 | $12,140,000.00 |
| Revenue This Year | N/A | $320.10 |
| Revenue Next Year | N/A | $100.00 |
| P/E Ratio | $8.36 | ★ N/A |
| Revenue Growth | N/A | ★ 73.43 |
| 52 Week Low | $12.72 | $0.61 |
| 52 Week High | $20.75 | $4.19 |
Technical Indicators
Market Signals| Indicator | HBB | PRLD |
|---|---|---|
| Relative Strength Index (RSI) | 53.44 | 53.86 |
| Support Level | $17.95 | $1.02 |
| Resistance Level | $20.33 | $4.10 |
| Average True Range (ATR) | 0.89 | 0.36 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 69.12 | 38.48 |
Price Performance
Historical ComparisonAbout HBB Hamilton Beach Brands Holding Company
Hamilton Beach Brands Holding Co, through its subsidiaries, is engaged in consumer, commercial, and specialty small appliances and specialty retail. It designs, markets, and distributes small branded electric household and specialty housewares small appliances, as well as commercial products for restaurants, bars, and hotels. It has two operating segments Home and Commercial Products and Health.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.